To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men (OCV)

EuBiologics

Status and phase

Completed

Phase 1

Conditions

Prevention Harmful Effects

Treatments

Biological: Euvichol

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01707537

UBC101

Details and patient eligibility

About

To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Full description

This clinical trial is open, non-comparative phase 1 clinical studies in healthy men and has been designed to determine the safety and immunogenicity of Euvichol(Oral cholera vaccine)

Enrollment

20 patients

Sex

Male

Ages

20+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adult men over 20years of age
More than 45kg body weight and ideal body weight within ±20% of the weight
Screening was conducted within 14 days of investigational drug administration (Vital Sign & Physical Examination, hematology and blood coagulation tests, blood chemistry tests, urinalysis, 12-lead ECG, etc.), the results at the discretion of the investigator deemed suitable for participation in clinical trials
Written consent person who determines to participate in a clinical trial

Exclusion criteria

A person who showed hypersensitivity when other preventive vaccination in the past
A person who have received cholera vaccine in the past
A person who had a febrile illness or infection disease, or have received antibiotics within 2weeks before the start of the experiment
A person who had gastrointestinal symptoms such as diarrhea, abdominal pain, or have been received prescription drug within one week before the start of the experiment
A person who was lasted for more than two weeks of symptoms such as diarrhea, abdominal pain within 6months before the start of the experiment
A person who donate whole blood or component of blood within one months before the start of the experiment if the donors
A person who received other preventive vaccine within 2months before the start of the experiment
A person who received blood products of immune globulin preparations within 3months before the start of the experiment
A person who has immune function disorders or are receiving immunosuppressive treatment
A person who has chronic illness in progress
Ongoing drug and alcohol abuse(Not more than 28 units/week for drinking)
A person who participate in clinical trials treated with the investigational drug within 2months before the start of the experiment
A person who is difficult to participate in this clinical trials as the discretion of the investigator